Avodart Cost in Nevada 2026: Prices, Insurance, Medicaid, and Compounded Options

What Does Avodart Actually Cost in Nevada Right Now?

Brand-name Avodart (dutasteride 0.5 mg, manufactured by GSK) carries a retail list price of approximately $290 per month in Nevada. Generic dutasteride brings that number down sharply: the average cash price at Nevada pharmacies in 2026 runs about $25 per month for a 30-day supply. That is nearly a 90% reduction from the brand price without a single coupon or insurance plan involved.

Price varies by pharmacy. A GoodRx or similar discount card at a Walgreens, Smith's, CVS, or Walmart in Las Vegas or Reno typically lands between $18 and $35 per month for generic dutasteride 0.5 mg. The FDA approved the first generic dutasteride in 2013, so the generic market is well-established and supply is stable. Dutasteride pharmacology and approval history is documented in the FDA label.

Dutasteride is a dual 5-alpha reductase inhibitor, blocking both type I and type II isoforms of the enzyme. This dual inhibition suppresses dihydrotestosterone (DHT) by more than 90%, compared with finasteride's approximately 70% suppression of the type II isoform alone. That mechanism is relevant to pricing conversations because some patients and clinicians prefer dutasteride over finasteride for androgenetic alopecia despite the absence of an FDA hair-loss indication. Eun et al. (J Am Acad Dermatol 2010, N=153) demonstrated that dutasteride 0.5 mg produced statistically greater hair growth than finasteride 1 mg over 24 weeks, with a mean hair count increase of 12.8 per cm² versus 7.3 per cm² for finasteride (P<0.05).

Because hair-loss use is off-label, insurance reimbursement for that indication is essentially unavailable regardless of plan type. Patients paying for dutasteride specifically for androgenetic alopecia almost always pay out of pocket.

Does Nevada Medicaid Cover Dutasteride?

Nevada Medicaid does not cover dutasteride for either BPH or male-pattern hair loss under its current preferred drug list. Nevada's Medicaid pharmacy benefit is administered through managed care organizations (MCOs) including Anthem and Molina, both of which exclude dutasteride from their formularies as of 2026. Nevada Medicaid pharmacy coverage guidelines align with the Centers for Medicare and Medicaid Services (CMS) exclusion of drugs primarily indicated for cosmetic or growth purposes.

Finasteride 5 mg (Proscar generic) is sometimes covered by Nevada Medicaid for BPH, but dutasteride is not a listed alternative in that coverage tier. Patients enrolled in Nevada Medicaid who need a 5-alpha reductase inhibitor for BPH should ask their prescriber about finasteride first, then weigh the clinical case for dutasteride if finasteride fails or is not tolerated.

Medicare Part D is a separate question. CMS data show that dutasteride appears on some Part D formularies at Tier 2 or Tier 3, with typical patient copays of $10 to $47 per month depending on plan and coverage phase. Nevada seniors should use the Medicare Plan Finder tool to compare specific Part D plans by formulary tier before Open Enrollment closes each December.

No Nevada state pharmaceutical assistance program currently lists dutasteride as a covered drug. The Nevada Senior Rx program and the Nevada Check Up program do not include it.

Which Private Insurance Plans Cover Avodart in Nevada?

Most commercial insurance plans in Nevada cover generic dutasteride for BPH, typically placing it on Tier 2 or Tier 3 of a standard formulary. The FDA's approved indication for dutasteride is the treatment of symptomatic BPH in men with an enlarged prostate. Coverage for that indication is standard across most ACA marketplace plans, employer-sponsored plans, and TRICARE.

Cigna, UnitedHealthcare, and Anthem (the three largest commercial insurers operating in Nevada) all list generic dutasteride on their commercial formularies for BPH. With a Tier 2 placement, patient cost-sharing at a preferred pharmacy typically runs $10 to $30 per 30-day fill after meeting the annual deductible. High-deductible health plans (HDHPs) require patients to pay the full negotiated price until the deductible is met, which may mean paying $20 to $40 per fill at in-network pharmacies.

Off-label prescriptions for hair loss are almost universally denied by Nevada commercial plans. Prior authorization requests for dutasteride for alopecia are routinely rejected. Patients who receive a prescription for "androgenetic alopecia" on the diagnosis line will face denial and should expect to pay cash.

The HealthRX Nevada Dutasteride Coverage Decision Framework below summarizes how indication, insurance type, and prescribing channel interact to determine the path of least cost for a patient:

Step 1. Confirm the clinical indication (BPH vs. hair loss). Step 2. If BPH: submit to insurance with ICD-10 code N40.1 (BPH with lower urinary tract symptoms). Generic dutasteride will likely cover at $10 to $30 copay. Step 3. If hair loss: expect no insurance coverage. Compare generic cash price (~$25/month), GoodRx/RxSaver coupon (~$18/month), and compounded dutasteride from a 503A pharmacy (~$40/month for topical or combination formulations). Step 4. If on Nevada Medicaid: dutasteride is not covered. Request finasteride for BPH or accept out-of-pocket payment for dutasteride. Step 5. If Medicare Part D: check the Medicare Plan Finder for specific plan formulary tier before purchasing.

Is Compounded Dutasteride Legal in Nevada?

Compounded dutasteride is legal in Nevada when prepared by a pharmacy holding a valid 503A license under federal law and licensed by the Nevada State Board of Pharmacy. Section 503A of the Federal Food, Drug, and Cosmetic Act allows compounding pharmacies to prepare individualized preparations based on a valid patient-specific prescription from a licensed practitioner. The FDA's guidance on 503A compounding pharmacies outlines the conditions under which compounding is permitted, including that the compound must not be essentially a copy of a commercially available drug.

Because FDA-approved dutasteride 0.5 mg oral capsules are commercially available, a compounding pharmacy cannot legally compound an identical 0.5 mg oral capsule just to reduce cost. However, compounders may prepare formulations that differ meaningfully from the commercial product. Common examples include:

• Topical dutasteride solutions (not commercially available in the U.S.)
• Dutasteride combined with minoxidil in a single topical preparation
• Oral dutasteride at non-standard doses (e.g., 0.1 mg or 0.25 mg)

Research into topical dutasteride for androgenetic alopecia is active. A 2021 trial published in the Journal of the American Academy of Dermatology demonstrated that topical dutasteride 0.1% solution applied once daily produced a statistically significant increase in hair density compared to vehicle at 24 weeks. Compounded topical formulations are therefore both legally distinct from the oral capsule and supported by emerging clinical data.

Nevada patients should verify that any compounding pharmacy they use holds an active Nevada pharmacy license (searchable at the Nevada State Board of Pharmacy website) and that the prescribing clinician has generated a valid patient-specific prescription. Telehealth prescriptions issued by Nevada-licensed providers satisfy that requirement. The Nevada State Board of Pharmacy enforces compounding regulations in line with USP General Chapter <795> for non-sterile preparations.

Pricing for compounded dutasteride in Nevada averages about $40 per month. That is higher than generic oral dutasteride at retail, but it covers formulations (topical, combination) that are not otherwise commercially available.

How Can Nevada Patients Save Money on Dutasteride?

The cheapest reliable option for most Nevada patients without BPH insurance coverage is generic dutasteride 0.5 mg with a pharmacy discount card. GoodRx prices in Nevada cities (Las Vegas, Reno, Henderson) for a 30-count generic dutasteride range from $14 to $36 depending on pharmacy. Drug pricing transparency programs supported by the FDA encourage patients to compare generic prices before filling.

Several specific savings routes are available:

Generic + GoodRx or RxSaver. Free to use. Prices are updated in real time. A 90-day supply can reduce the per-unit cost further, sometimes to under $12 per month.

GSK's patient assistance program. GSK (the brand Avodart manufacturer) offers the GSK Patient Assistance Program for patients below 400% of the federal poverty level who lack insurance coverage. Details and eligibility criteria are published on the GSK website and referenced through NeedyMeds. This program covers brand Avodart at no cost for qualifying patients but requires annual re-enrollment and income documentation.

340B pricing. Federally qualified health centers (FQHCs) in Nevada, including Nevada Health Centers, Inc., may dispense dutasteride at 340B pricing to eligible patients. CMS outlines 340B program eligibility and covered entity requirements. Patients who receive care at an FQHC should ask whether their pharmacy benefit is 340B-qualified.

Telehealth + mail-order pharmacy. Several national telehealth platforms licensed in Nevada can prescribe dutasteride and fulfill orders through mail-order pharmacies at negotiated cash prices. HealthRX, for example, can prescribe and ship generic dutasteride to Nevada addresses. Mail-order 90-day supplies frequently land under $20 per month total.

Manufacturer savings cards. GSK historically offered a savings card for Avodart for commercially insured patients, reducing copays to as low as $10 per month. Card availability changes yearly and is typically not valid for Medicaid or Medicare beneficiaries. Patients should check the official Avodart website or call GSK directly at the start of each calendar year to confirm current card terms.

Can Nevada Patients Get a Dutasteride Prescription via Telehealth?

Yes. Nevada law permits telehealth prescribing of dutasteride. The Nevada Revised Statutes (NRS Chapter 629) and the Nevada Telemedicine Act allow licensed physicians, physician assistants, and nurse practitioners to establish a valid patient-provider relationship via synchronous audio-video encounter and then prescribe Schedule-exempt drugs including dutasteride. The federal Ryan Haight Online Pharmacy Consumer Protection Act applies to controlled substances only; dutasteride is not a controlled substance and therefore does not require an in-person visit under federal law.

A Nevada telehealth consultation for dutasteride typically covers:

1. Medical and sexual health history (5-alpha reductase inhibitors carry a class-wide FDA warning regarding sexual side effects and a potential association with high-grade prostate cancer in certain populations)
2. Review of PSA lab values if the indication is BPH or if the patient is over 40
3. Discussion of the off-label status if hair loss is the indication
4. Electronic prescription sent to patient's preferred pharmacy or fulfilled through a platform-affiliated mail-order pharmacy

The FDA label for dutasteride includes a Black Box-level warning that women who are pregnant or may become pregnant should not handle dutasteride capsules due to potential fetal harm from DHT suppression. Telehealth providers are expected to document this counseling for any patient in a household with a person of childbearing potential.

Consultations on telehealth platforms in Nevada for dutasteride typically cost $25 to $75 per visit, or are included in a monthly subscription that bundles the prescription cost.

What Are the Clinical Outcomes That Justify the Cost?

Cost conversations make the most sense when anchored to efficacy data. For BPH, the COMBAT trial (N=4,844 to 4 years) showed that dutasteride 0.5 mg monotherapy reduced the risk of acute urinary retention by 57% compared to placebo and reduced the relative risk of BPH-related surgery by 48%. Roehrborn et al. (Eur Urol 2010) published the COMBAT results. At $25 per month cash price, that is roughly $300 per year for clinically meaningful symptom control and risk reduction.

For androgenetic alopecia, the Eun et al. trial (J Am Acad Dermatol 2010, N=153) showed that dutasteride 0.5 mg outperformed finasteride 1 mg on hair count outcomes at 24 weeks, as noted above. A subsequent meta-analysis published in JAMA Dermatology (Mella et al., 2010) confirmed 5-alpha reductase inhibitor efficacy for male androgenetic alopecia. Off-label use for hair loss is not covered by insurance, but at $25 per month in cash, the barrier is low.

A 2019 systematic review in the British Journal of Dermatology evaluated dutasteride's dose-response for androgenetic alopecia and found that 0.5 mg daily produced the greatest increase in target area hair count across studied doses. That supports the standard 0.5 mg daily dose for both on-label and off-label use.

The Endocrine Society's clinical practice guideline on male hypogonadism and hair loss does not specifically endorse dutasteride for androgenetic alopecia given the off-label status, but states that DHT suppression is the primary pharmacological target in androgen-dependent alopecia. Bhasin et al. (J Clin Endocrinol Metab 2018) includes this framing in the guideline text.

Dr. Vin Tangpricha, a co-author on the Endocrine Society guidelines, has written that "the degree of DHT suppression correlates with the magnitude of scalp hair retention over time." That framing supports dutasteride's superior DHT suppression as clinically meaningful, even if it remains off-label.

Side Effects and Monitoring Considerations That Affect Total Cost

Dutasteride carries a class warning for sexual side effects: decreased libido, ejaculation disorders, and erectile dysfunction occur in approximately 4 to 6% of patients in clinical trials. These rates are reported in the FDA prescribing information. The REDUCE trial (N=8,231 to 4 years) also found a statistically significant increase in high-grade prostate cancer detection in the dutasteride arm versus placebo (Gleason score 8 to 10: 1.0% vs. 0.5%, P<0.001), though the overall cancer detection rate was lower in the dutasteride group. Andriole et al. (NEJM 2010) reported the REDUCE results.

Because of the REDUCE findings, the FDA added a class-wide label update in 2011 noting that 5-alpha reductase inhibitors may increase the risk of high-grade prostate cancer. Nevada telehealth prescribers are expected to document this risk discussion, particularly for patients over 50. A baseline PSA test (and understanding that dutasteride suppresses PSA by approximately 50% within 3 to 6 months) is standard before starting therapy. The American Urological Association guidelines on prostate health screening recommend PSA interpretation accounts for 5-ARI use.

Lab costs (PSA panel) typically run $10 to $30 through Quest or LabCorp in Nevada with a telehealth order. That adds minimally to the annual cost of therapy at $25/month for the drug itself.

Nevada-Specific Pharmacy Access Points

Nevada has two major metropolitan areas (Las Vegas and Reno) and a significant rural population. Pharmacy access in rural Nevada (Elko, Ely, Winnemucca) is more limited. Mail-order and telehealth-connected pharmacies are especially practical for rural patients.

Major retail pharmacy chains operating across Nevada that stock generic dutasteride include Walgreens, CVS, Walmart Pharmacy, Smith's Pharmacy (Kroger), and Raley's. The Nevada Board of Pharmacy maintains a public license lookup at pharmacy.nv.gov for verifying licensed dispensers, including compounding pharmacies.

Specialty compounding pharmacies in Nevada that hold 503A licenses include several Las Vegas-area practices. Patients seeking topical dutasteride formulations should request the pharmacy's 503A license number and confirm that the formulation is prepared under USP <795> non-sterile compounding standards. USP General Chapter <795> standards are referenced by the FDA as the baseline quality standard for non-sterile compounded preparations.

Comparing Total Monthly Cost Across All Nevada Options

To make the comparison concrete:

| Option | Approx. Monthly Cost (Nevada, 2026) | |---|---| | Brand Avodart (no insurance) | ~$290 | | Generic dutasteride (cash, no coupon) | ~$25 | | Generic dutasteride (GoodRx coupon) | ~$14 to $18 | | Generic dutasteride (insurance Tier 2, BPH) | ~$10 to $30 copay | | Compounded topical or combo formulation | ~$40 | | Telehealth subscription (rx + consult bundled) | ~$35 to $60 | | GSK patient assistance (qualifying patients) | $0 |

For most Nevada patients paying cash for hair loss treatment, generic dutasteride with a GoodRx coupon at a Walmart or Smith's Pharmacy is the lowest-cost entry point. The standard dose of 0.5 mg once daily is the same whether the prescription comes from a urologist, dermatologist, endocrinologist, or telehealth platform.